for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Limited

PFIZ.NS

Latest Trade

3,211.00INR

Change

15.35(+0.48%)

Volume

3,212

Today's Range

3,184.00

 - 

3,231.95

52 Week Range

2,626.05

 - 

3,488.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Latest Developments

India's Pfizer Ltd March-qtr Profit Rises

May 28 (Reuters) - Pfizer Ltd <PFIZ.NS>::PFIZER LTD RECOMMENDED DIVIDEND OF 22.5 RUPEES PER SHARE.MARCH QUARTER NET PROFIT 1.09 BILLION RUPEES VERSUS 1.05 BILLION RUPEES YEAR AGO.MARCH QUARTER REVENUE FROM OPERATIONS 5.36 BILLION RUPEES VERSUS 5.20 BILLION RUPEES YEAR AGO.

EMA Says CHMP Recommends Granting A Conditional Marketing Authorisation For Waylivra

March 1 (Reuters) - EMA - :EMA - CHMP RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR ONDEXXYA.EMA - CHMP RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR WAYLIVRA.EMA - ZYNQUISTA INTENDED AS AN ADJUNCT TO INSULIN FOR CERTAIN PATIENTS WITH TYPE 1 DIABETES, RECEIVED A POSITIVE OPINION FROM CHMP.EMA - CHMP ADOPTED A POSITIVE OPINION, RECOMMENDING GRANTING OF A CONDITIONAL MARKETING AUTHORISATION FOR LORVIQUA.EMA - CHMP RECOMMENDED FOR APPROVAL GENERIC MEDICINE PAZENIR FOR TREATMENT OF METASTATIC BREAST CANCER AND NON-SMALL CELL LUNG CANCER.EMA - APPLICANT FOR DOXOLIPAD HAS REQUESTED A RE-EXAMINATION OF COMMITTEE'S NEGATIVE OPINION FOR THIS MEDICINE ADOPTED AT JANUARY 2019 MEETING.EMA - CHMP RECOMMENDED EXTENSION OF INDICATION OF DUPIXENT AS ADD-ON MAINTENANCE TREATMENT FOR PATIENTS 12 YRS & OLDER WITH FORMS OF SEVERE ASTHMA.EMA - CHMP WILL NOW RE-EXAMINE OPINION FOR DOXOLIPAD AND ISSUE A FINAL RECOMMENDATION.EMA - APPLICATION FOR AN INITIAL MARKETING AUTHORISATION FOR EPJEVY (PACRITINIB CITRATE) WAS WITHDRAWN.EMA - OTHER EXTENSIONS OF INDICATION RECOMMENDED BY COMMITTEE WERE FOR LYNPARZA, RIARIFY, TRYDONIS AND VIREAD.

India's Pfizer Dec-Qtr Profit Rises

Jan 24 (Reuters) - Pfizer Ltd <PFIZ.NS>::DEC QUARTER NET PROFIT 1.32 BILLION RUPEES VERSUS 872.4 MILLION RUPEES YEAR AGO.DEC QUARTER REVENUE FROM OPERATIONS 5.14 BILLION RUPEES VERSUS 4.57 BILLION RUPEES YEAR AGO.

India's Pfizer Appoints Milind Patil As CFO

Aug 16 (Reuters) - Pfizer Ltd <PFIZ.NS>::SAYS APPOINTMENT OF MILIND PATIL AS CHIEF FINANCIAL OFFICER.

India's Pfizer June-Qtr Profit Rises

Aug 2 (Reuters) - Pfizer Ltd <PFIZ.NS>::JUNE QUARTER NET PROFIT 918.4 MILLION RUPEES VERSUS 571.7 MILLION RUPEES YEAR AGO.JUNE QUARTER REVENUE FROM OPERATIONS 5.12 BILLION RUPEES VERSUS 4.33 BILLION RUPEES YEAR AGO.

India's Pfizer March Qtr Profit Rises

May 7 (Reuters) - Pfizer Ltd <PFIZ.NS>::MARCH QUARTER NET PROFIT 1.05 BILLION RUPEES VERSUS PROFIT OF 680.4 MILLION RUPEES YEAR AGO.MARCH QUARTER REVENUE FROM OPERATIONS 5.20 BILLION RUPEES VERSUS 4.53 BILLION RUPEES YEAR AGO.RECOMMENDED DIVIDEND OF 20 RUPEES PER SHARE.

Pfizer Ltd Says Pfizer Inc Has Not Yet Made Decision w.r.t Strategic Alternatives For Global Consumer Healthcare Business​

March 1 (Reuters) - Pfizer Ltd <PFIZ.NS>::‍PFIZER INC. TOLD CO'S BOARD THAT NO DECISION HAS YET BEEN MADE WITH RESPECT TO ANY STRATEGIC ALTERNATIVES FOR GLOBAL CONSUMER HEALTHCARE BUSINESS​.PFIZER INC IDENTIFIED PRODUCTS OUTSIDE CONSUMER HEALTHCARE BUSINESS IN INDIA TO BE INCLUDED STRATEGIC ALTERNATIVES REVIEW FOR BUSINESS.

Pfizer Says Ravi Prakash Bhagavathula Resigned As CFO

Feb 19 (Reuters) - Pfizer Ltd <PFIZ.NS>::SAYS RAVI PRAKASH BHAGAVATHULA RESIGNED AS CFO.

India's Pfizer Dec-Qtr Profit Rises

Jan 24 (Reuters) - Pfizer Ltd <PFIZ.NS>::DEC QUARTER NET PROFIT 872.4 MILLION RUPEES VERSUS PROFIT OF 623.7 MILLION RUPEES YEAR AGO.DEC QUARTER REVENUE FROM OPERATIONS 4.57 BILLION RUPEES VERSUS 5.10 BILLION RUPEES YEAR AGO.

FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

Dec 22 (Reuters) - Merck & Co Inc <MRK.N>::FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES.MERCK & CO INC - FDA APPROVED STEGLATRO TABLETS, AN ORAL SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR, AND FIXED-DOSE COMBINATION STEGLUJAN TABLETS.MERCK & CO INC - IN ADDITION TO STEGLATRO & STEGLUJAN, FDA ALSO APPROVED FIXED-DOSE COMBINATION SEGLUROMET.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up